ArticleCureus2024
Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic re-irradiation has a high risk of severe adverse events, and re-irradiation with curative intent has rarely been performed. However, in recent years, with the introduction of intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy, it has become possible to deliver high doses to the target lesions while minimizing the doses to surrounding tissues. The patient in this case had a history of definitive radiation therapy for esophageal cancer. The patient developed new lung cancer, which was treated by re-irradiation. We created a radiation treatment plan using IMRT. This allowed us to reduce the dose to organs at risk and deliver a higher dose to the cancer, increasing the potential for cure. The patient has not experienced any severe late adverse events as of three years and six months after treatment. Additionally, the treatment has been sufficiently effective, and the patient remains recurrence-free. To confirm the feasibility of the IMRT plan, we also created a radiation treatment plan using three-dimensional conformal radiation therapy (3D-CRT) and compared it with the IMRT plan. Compared with 3D-CRT, the IMRT plan was able to reduce the dose to organs at risk and meet the dose constraints indicated in multiple studies. The possibility of adverse events such as bronchial hemorrhage, esophageal hemorrhage, bronchial fistula, radiation pneumonitis, esophageal fistula, and pericarditis was significantly reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.